Drug intelligence / Profile preview

ABBV-291

Development stage: Phase 1
Lead developer: AbbVie
Modality: Small Molecules
Administration: Intravenous

Overview

ABBV-291 is an investigational antineoplastic drug being developed by AbbVie for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL), including subtypes such as diffuse large B-cell lymphoma, follicular lymphoma, lymphoblastic lymphoma, mantle cell lymphoma, marginal zone lymphoma, and Waldenström macroglobulinemia. It is currently in Phase 1 clinical trials to determine its safety profile, pharmacokinetics, and efficacy in adults who have failed at least two prior lines of therapy. The precise mechanism of action has not been publicly defined as of the latest updates, but it is classified broadly as an antineoplastic agent. The drug is administered intravenously and trial participants are monitored for adverse events and changes in disease activity over a multi-year study period.

Other names: ABBV 291ABBV291ABBV-291

Beyond the preview

Go deeper on ABBV-291.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABBV-291.